{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:03Z","timestamp":1792601043552,"version":"4.5.0"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital of China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700216"],"award-info":[{"award-number":["81700216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118163","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:08:20Z","timestamp":1757549300000},"page":"118163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide"],"prefix":"10.1016","volume":"300","author":[{"given":"Xinyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118163_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2025.118163_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"45","key":"10.1016\/j.ejmech.2025.118163_bib4","first-page":"1066","article-title":"Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002","volume":"53","year":"2004","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118163_bib5","first-page":"2237","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-025-00264-9","article-title":"Obesity: pathophysiology and therapeutic interventions","volume":"6","author":"Kong","year":"2025","journal-title":"Molecular biomedicine"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118163_bib7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2025.118163_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2025.118163_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171179","article-title":"GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells","volume":"175","author":"Shilleh","year":"2024","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"issue":"49","key":"10.1016\/j.ejmech.2025.118163_bib11","doi-asserted-by":"crossref","first-page":"81077","DOI":"10.18632\/oncotarget.13189","article-title":"Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118163_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116342","article-title":"Glucagon-like peptide-1 analogs: miracle drugs are blooming?","volume":"269","author":"Gong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118163_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29163909","article-title":"The synthesis of SNAC Phenolate Salts and the effect on oral bioavailability of semaglutide","volume":"29","author":"Shapira-Furman","year":"2024","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA : Off. J. Am. Acad. Physician Assistants (JAAPA)"},{"key":"10.1016\/j.ejmech.2025.118163_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2025.118163_bib21","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"sup1","key":"10.1016\/j.ejmech.2025.118163_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"PGM (Postgrad. Med.)"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.118163_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118163_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14995","article-title":"Gut neuropathies and intestinal motility disorders","author":"Wattchow","year":"2025","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.ejmech.2025.118163_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2025.1532900","article-title":"Imaging the enteric nervous system","volume":"19","author":"Hazart","year":"2025","journal-title":"Front. Neuroanat."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118163_bib26","article-title":"Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors","volume":"22","author":"Amato","year":"2010","journal-title":"Neuro Gastroenterol. Motil."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/bph.15603","article-title":"Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating","volume":"179","author":"Brierley","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118163_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1566-0702(02)00182-0","article-title":"Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons","volume":"102","author":"Kakei","year":"2002","journal-title":"Auton Neurosci. Basic Clin."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib29","article-title":"Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat","volume":"21","author":"Bucinskaite","year":"2009","journal-title":"Neuro Gastroenterol. Motil."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0016-5085(84)90411-6","article-title":"Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon","volume":"86","author":"Read","year":"1984","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118163_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.ejmech.2025.118163_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118163_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuroscience.2011.02.023","article-title":"Preproglucagon neurons project widely to autonomic control areas in the mouse brain","volume":"180","author":"Llewellyn-Smith","year":"2011","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib34","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118163_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101352","article-title":"Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo","volume":"54","author":"Dong","year":"2021","journal-title":"Mol. Metabol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s42255-022-00611-y","article-title":"Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding","volume":"4","author":"Alcantara","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejmech.2025.118163_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Mol. Metabol."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118163_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178239","article-title":"GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice","volume":"134","author":"Chen","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10787-024-01603-y","article-title":"Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota-gut--brain axis in obese mice","volume":"33","author":"da Silva","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 Analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2025.118163_bib41","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17891","article-title":"Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice","volume":"12","author":"Feng","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.ejmech.2025.118163_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176440","article-title":"Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet","volume":"969","author":"Duan","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib44","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","article-title":"Effect of oral semaglutide on the pharmacokinetics of Lisinopril, Warfarin, Digoxin, and metformin in healthy subjects","volume":"58","author":"B\u00e6kdal","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib45","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc20-0720","article-title":"Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on Esophageal and gastric function in patients with type 2 diabetes","volume":"43","author":"Quast","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib46","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Canadian journal of anaesthesia = Journal canadien d'anesthesie"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s12630-023-02549-5","article-title":"Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide","volume":"70","author":"Sherwin","year":"2023","journal-title":"Canadian journal of anaesthesia = Journal canadien d'anesthesie"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib48","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg. Obes. Relat. Dis. : official journal of the American Society for Bariatric Surgery"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/ALN.0000000000001515","article-title":"Perioperative hyperglycemia management: an update","volume":"126","author":"Duggan","year":"2017","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1213\/ANE.0000000000003372","article-title":"Diagnostic accuracy of point-of-care gastric ultrasound","volume":"128","author":"Kruisselbrink","year":"2019","journal-title":"Anesth. Analg."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib51","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/jdi.14229","article-title":"A real-world disproportionality analysis of semaglutide: post-marketing pharmacovigilance data","volume":"15","author":"Du","year":"2024","journal-title":"Journal of diabetes investigation"},{"issue":"18","key":"10.1016\/j.ejmech.2025.118163_bib52","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118163_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front. Public Health"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib54","first-page":"108","article-title":"Appendicitis: a hidden Danger of GLP-1 receptor agonists?","volume":"40","author":"Casella","year":"2024","journal-title":"J. Pharm. Technol. : jPT : official publication of the Association of Pharmacy Technicians"},{"key":"10.1016\/j.ejmech.2025.118163_bib55","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(15)00275-5","article-title":"Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management","volume":"386","author":"Bhangu","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"PGM (Postgrad. Med.)"},{"issue":"10 Suppl 18","key":"10.1016\/j.ejmech.2025.118163_bib57","first-page":"4","article-title":"Treatment challenges in the management of gastroparesis-related GERD","volume":"5","author":"Fass","year":"2009","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118163_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.118163_bib59","article-title":"Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases","author":"Zhou","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib60","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined Glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area postrema cell types that mediate nausea-associated behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118163_bib62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib63","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1111\/dom.16508","article-title":"Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes","volume":"27","author":"Ciudin","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","article-title":"Exenatide (exendin-4)-induced pancreatitis: a case report","volume":"29","author":"Denker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2025.118163_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/00185787251321072","article-title":"Idiopathic and metabolic triggers leading to recurrent acute pancreatitis in a 30-year-old woman","author":"Ahmed","year":"2025","journal-title":"Hosp. Pharm."},{"issue":"40","key":"10.1016\/j.ejmech.2025.118163_bib66","doi-asserted-by":"crossref","first-page":"37317","DOI":"10.1074\/jbc.M104378200","article-title":"A coding region determinant of instability regulates levels of manganese superoxide dismutase mRNA","volume":"276","author":"Davis","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118163_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231320","article-title":"Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118163_bib69","article-title":"Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: a multicenter analysis","author":"Nieto","year":"2025","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","article-title":"Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis","volume":"45","author":"Cao","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metabol. Syndr."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib72","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data","volume":"117","author":"Wang","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13046-024-03263-w","article-title":"The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration","volume":"44","author":"Cencioni","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118163_bib74","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mce.2012.08.010","article-title":"\u03b2-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic \u03b2 INS832\/13 cells","volume":"364","author":"Talbot","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"35","key":"10.1016\/j.ejmech.2025.118163_bib75","doi-asserted-by":"crossref","first-page":"32517","DOI":"10.1074\/jbc.M301174200","article-title":"Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells","volume":"278","author":"Arnette","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.ejmech.2025.118163_bib76","doi-asserted-by":"crossref","first-page":"48146","DOI":"10.1074\/jbc.M209165200","article-title":"cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells","volume":"277","author":"Gomez","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib77","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1074\/jbc.M109.067207","article-title":"GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1\/2 activation in pancreatic beta-cells","volume":"285","author":"Quoyer","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1748-1716.2007.01785.x","article-title":"The protein kinases ERK1\/2 and their roles in pancreatic beta cells","volume":"192","author":"Lawrence","year":"2008","journal-title":"Acta Physiol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","article-title":"Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death","volume":"80","author":"Yang","year":"1995","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ejmech.2025.118163_bib80","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1101\/gad.1097103","article-title":"cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2","volume":"17","author":"Jhala","year":"2003","journal-title":"Genes Dev."},{"issue":"5708","key":"10.1016\/j.ejmech.2025.118163_bib81","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1126\/science.1104345","article-title":"Type 2 diabetes-a matter of beta-cell life and death?","volume":"307","author":"Rhodes","year":"2005","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.ejmech.2025.118163_bib82","unstructured":"!!! INVALID CITATION !!! [82]."},{"key":"10.1016\/j.ejmech.2025.118163_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102346","article-title":"The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC\/YAP signaling pathway","volume":"54","author":"Ma","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2025.118163_bib84","article-title":"Activation of CREB drives acinar cells to ductal reprogramming and promotes pancreatic cancer progression in animal models of alcoholic pancreatitis","author":"Srinivasan","year":"2025","journal-title":"bioRxiv : the preprint server for biology"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib85","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr. Pract. : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel","volume":"55","author":"Kapitza","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib87","article-title":"Acute pancreatitis likely due to semaglutide","volume":"16","author":"Hughes","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib88","article-title":"Exocrine pancreatic insufficiency during the Use of semaglutide: a case report","volume":"16","author":"Agra de Melo Junior","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib89","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am. J. Physiol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib90","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib91","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2006.116087","article-title":"Experimental acute pancreatitis in PAP\/HIP knock-out mice","volume":"56","author":"Gironella","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib92","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12967-025-06304-w","article-title":"FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118163_bib93","doi-asserted-by":"crossref","DOI":"10.1089\/omi.2024.0216","article-title":"Explaining type 2 diabetes with transcriptomic signatures of pancreatic \u03b2-cell dysfunction and death induced by human islet amyloid polypeptide","author":"Roham","year":"2025","journal-title":"OMICS A J. Integr. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib94","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/dom.12879","article-title":"Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes","volume":"19","author":"Kirk","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib95","doi-asserted-by":"crossref","first-page":"G26","DOI":"10.1152\/ajpgi.00293.2015","article-title":"Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP","volume":"310","author":"Hou","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib96","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib98","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod. Pathol. : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib99","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.scr.2015.05.006","article-title":"Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair","volume":"15","author":"Yamaguchi","year":"2015","journal-title":"Stem Cell Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib101","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1053\/j.gastro.2009.12.005","article-title":"Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia","volume":"138","author":"Strobel","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib102","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.15003","article-title":"Intraductal neoplasms of the pancreatobiliary tract: navigating the alphabet","volume":"83","author":"Xue","year":"2023","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib103","first-page":"306","article-title":"Update on pancreatic intraepithelial neoplasia","volume":"1","author":"Hruban","year":"2008","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yexcr.2015.11.002","article-title":"Isolation and characterization of human islet stellate cells","volume":"341","author":"Zha","year":"2016","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/labinvest.2013.133","article-title":"PSCs and GLP-1R: occurrence in normal pancreas, acute\/chronic pancreatitis and effect of their activation by a GLP-1R agonist","volume":"94","author":"Nakamura","year":"2014","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.pan.2013.07.281","article-title":"GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion","volume":"13","author":"Yang","year":"2013","journal-title":"Pancreatology : official journal of the International Association of Pancreatology (IAP)"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib107","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118163_bib108","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00125-010-1849-y","article-title":"Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients","volume":"53","author":"Pugazhenthi","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2025.118163_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116849","article-title":"The function of microRNA related to cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"236","author":"Fang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118163_bib110","article-title":"PLXDC1(+) tumor-associated pancreatic stellate cells promote Desmoplastic and immunosuppressive niche in pancreatic ductal adenocarcinoma","author":"Du","year":"2025","journal-title":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib111","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118163_bib112","doi-asserted-by":"crossref","first-page":"G1474","DOI":"10.1152\/ajpgi.00562.2006","article-title":"Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons","volume":"292","author":"Wan","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2003.09.004","article-title":"Sensory circumventricular organs: central roles in integrated autonomic regulation","volume":"117","author":"Cottrell","year":"2004","journal-title":"Regul. Pept."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118163_bib114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.pan.2022.05.005","article-title":"Identification of high-risk germline variants for the development of pancreatic cancer: common characteristics and potential guidance to screening guidelines","volume":"22","author":"Bennett","year":"2022","journal-title":"Pancreatology : official journal of the International Association of Pancreatology (IAP)"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/08971900241273188","article-title":"Problematic pharmacokinetics: a case of recurrent pancreatitis post discontinuation of a glucagon-like peptide 1 receptor agonists","volume":"38","author":"Morehouse","year":"2025","journal-title":"J. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib116","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9343(99)80394-5","article-title":"Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation","volume":"98","author":"Weinsier","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2025.118163_bib117","article-title":"Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib118","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13098-024-01526-2","article-title":"The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study","volume":"16","author":"Gameil","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejmech.2025.118163_bib119","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"Abrahami","year":"2018","journal-title":"BMJ (Clinical research ed)"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib120","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","article-title":"Use of incretin-based drugs and risk of cholangiocarcinoma: scandinavian cohort study","volume":"64","author":"Ueda","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib121","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i1.99960","article-title":"Effect of cholesterol metabolism on hepatolithiasis","volume":"31","author":"Zheng","year":"2025","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib122","first-page":"172","article-title":"Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis","volume":"58","author":"Ben-Shlomo","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib123","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib124","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118163_bib125","series-title":"Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging - IDKD Book","first-page":"49","article-title":"IDKD springer Series disease of the gallbladder and biliary tree","author":"Lee","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118163_bib126","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJM196209272671303","article-title":"Cholecystitis and diabetes mellitus","volume":"267","author":"Mundth","year":"1962","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib127","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/dom.12689","article-title":"Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118163_bib129","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11892-013-0411-y","article-title":"Hypoglycemia in patients with type 1 diabetes: epidemiology, pathogenesis, and prevention","volume":"13","author":"Awoniyi","year":"2013","journal-title":"Curr. Diabetes Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118163_bib131","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1111\/dom.13422","article-title":"Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: a randomized, placebo-controlled, double-blind, crossover trial","volume":"20","author":"Korsatko","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib132","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1111\/dom.15794","article-title":"Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme","volume":"26","author":"Yale","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202563","article-title":"Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"13","author":"Qian","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib135","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/gerona\/glad075","article-title":"Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk","volume":"78","author":"Htoo","year":"2023","journal-title":"The journals of gerontology Series A, Biological sciences and medical sciences"},{"key":"10.1016\/j.ejmech.2025.118163_bib136","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"Suppl 7","key":"10.1016\/j.ejmech.2025.118163_bib137","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dom.15883","article-title":"Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes","volume":"26","author":"Hirsch","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118163_bib138","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib139","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13030728","article-title":"Targeting diabetic atherosclerosis: the role of GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in vascular protection and disease modulation","volume":"13","author":"Rroji","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118163_bib141","doi-asserted-by":"crossref","unstructured":"Seufert J, Nauck M, Rosenstock J et al.: P2857Increase in pulse rate with semaglutide did not result in increas ed adverse cardiac events in subjects with type 2 diabetes in the SUST AIN 6 cardiovascular outcomes trial. Eur. Heart J., 39(suppl_1).","DOI":"10.1093\/eurheartj\/ehy565.P2857"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib142","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118163_bib143","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.neuroscience.2014.10.043","article-title":"Spinally projecting preproglucagon axons preferentially innervate sympathetic preganglionic neurons","volume":"284","author":"Llewellyn-Smith","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2025.118163_bib144","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.12.039","article-title":"Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats","volume":"344","author":"Oshima","year":"2017","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.mce.2008.10.039","article-title":"Angiotensin modulation of rostral ventrolateral medulla (RVLM) in cardiovascular regulation","volume":"302","author":"Bourassa","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib146","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-8993(01)02053-4","article-title":"Hypothalamic projections to cardiovascular centers of the medulla","volume":"894","author":"Hardy","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2025.118163_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101024","article-title":"PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice","volume":"39","author":"Holt","year":"2020","journal-title":"Mol. Metabol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib148","first-page":"E784","article-title":"Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats","volume":"277","author":"Barrag\u00e1n","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118163_bib149","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1210\/endo.138.10.5270","article-title":"Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat","volume":"138","author":"Larsen","year":"1997","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118163_bib150","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.molmet.2017.08.010","article-title":"The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice","volume":"6","author":"Baggio","year":"2017","journal-title":"Mol. Metabol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib151","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib152","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","article-title":"Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node","volume":"120","author":"Lubberding","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2025.118163_bib153","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.regpep.2004.08.024","article-title":"Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism","volume":"125","author":"Nystr\u00f6m","year":"2005","journal-title":"Regul. Pept."},{"issue":"38","key":"10.1016\/j.ejmech.2025.118163_bib154","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13098-022-00970-2","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Wu","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118163_bib156","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.116.024279","article-title":"Patients with long-QT syndrome caused by impaired hERG-Encoded K(v)11.1 potassium channel have Exaggerated endocrine pancreatic and incretin function associated with reactive hypoglycemia","volume":"135","author":"Hylt\u00e9n-Cavallius","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib157","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12863-018-0602-2","article-title":"Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses","volume":"19","author":"Engelbrechtsen","year":"2018","journal-title":"BMC Genet."},{"key":"10.1016\/j.ejmech.2025.118163_bib158","doi-asserted-by":"crossref","DOI":"10.2337\/dc25-0472","article-title":"Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a flow trial prespecified secondary analysis","author":"Rossing","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17070943","article-title":"Long-term effect of semaglutide on the glomerular filtration rate slope in high-risk patients with diabetic nephropathy: analysis in real-world clinical practice","volume":"17","author":"Luna","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfae150","article-title":"Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6","volume":"40","author":"Apperloo","year":"2025","journal-title":"Nephrol. Dial. Transplant. : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib161","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib162","article-title":"Assessing the renal outcomes of semaglutide in diabetic kidney disease: a systematic review","volume":"16","author":"Rehman","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2025.118163_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1551136","article-title":"GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism","volume":"16","author":"Peng","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib164","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.xkme.2020.10.008","article-title":"Acute kidney injury associated with semaglutide","volume":"3","author":"Leehey","year":"2021","journal-title":"Kidney medicine"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib165","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae250","article-title":"Semaglutide-associated kidney injury","volume":"17","author":"Begum","year":"2024","journal-title":"Clinical kidney journal"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib166","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000543357","article-title":"Minimal change podocytopathy with coexistent thin glomerular basement membrane following exposure to semaglutide","volume":"5","author":"Kovvuru","year":"2025","journal-title":"Glomerular Dis."},{"key":"10.1016\/j.ejmech.2025.118163_bib167","doi-asserted-by":"crossref","unstructured":"Attieh RM, Kirby G, Yihe Y et al.: Diffuse podocytopathy associated with semaglutide. AIM Clinical Cases, 3(5).","DOI":"10.7326\/aimcc.2023.1383"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib168","doi-asserted-by":"crossref","first-page":"Itc66","DOI":"10.7326\/AITC201711070","article-title":"Acute kidney injury","volume":"167","author":"Levey","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib169","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ekir.2024.09.026","article-title":"Clinicopathological characteristics and kidney outcomes in Biopsy-confirmed acute interstitial nephritis","volume":"9","author":"Miao","year":"2024","journal-title":"Kidney international reports"},{"key":"10.1016\/j.ejmech.2025.118163_bib172","series-title":"Acute Kidney Injury: Prevention, Detection and Management","article-title":"Clinical guidelines","year":"2024"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib173","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.118163_bib174","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/liv.14349","article-title":"EASL clinical practice guidelines for the management of occupational liver diseases","volume":"40","author":"Colombo","year":"2020","journal-title":"Liver Int. : official journal of the International Association for the Study of the Liver"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib175","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.70021","article-title":"Efficacy of hypoglycemic agents in metabolic dysfunction associated Steatotic liver disease (MASLD): a systematic review and network meta-analysis","volume":"18","author":"Ren","year":"2025","journal-title":"J. Evidence-based Med."},{"key":"10.1016\/j.ejmech.2025.118163_bib176","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci. : official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib177","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000922","article-title":"Progressive Cholestasis and biliary cirrhosis after initiating oral semaglutide: report from the drug-induced liver injury network","volume":"9","author":"Ma","year":"2022","journal-title":"ACG case reports journal"},{"key":"10.1016\/j.ejmech.2025.118163_bib178","doi-asserted-by":"crossref","unstructured":"Enslin S, Bartell N, Kaul V: S2727 the first reported case of drug-induced liver injury caused by S emaglutide. Am. J. Gastroenterol., 116(1):S1141-S1141.","DOI":"10.14309\/01.ajg.0000784440.97741.d2"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib179","article-title":"Semaglutide-induced lupus erythematosus with multiorgan involvement","volume":"16","author":"Castellanos","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib181","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","year":"1998","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib182","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108376","article-title":"Human tau promotes Warburg effect-like glycolytic metabolism under acute hyperglycemia conditions","volume":"301","author":"Yao","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib184","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s13300-023-01381-w","article-title":"GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers","volume":"14","author":"Heinla","year":"2023","journal-title":"Diabetes therapy : research, treatment and education of diabetes and related disorders"},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2025.118163_bib185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ghir.2014.01.003","article-title":"GLP-1 infusion reduces IGFBP-1 serum level in humans","volume":"24","author":"Skov","year":"2014","journal-title":"Growth Hormone IGF Res. : official journal of the Growth Hormone Research Society and the International IGF Research Society"},{"key":"10.1016\/j.ejmech.2025.118163_bib186","doi-asserted-by":"crossref","unstructured":"Lim SW, van Wijngaarden P, Harper CA et al.: Early worsening of diabetic retinopathy due to intensive glycaemic con trol. Clin. Exp. Ophthalmol., 47(2):265-273.","DOI":"10.1111\/ceo.13393"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib187","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jocn.2009.04.002","article-title":"Non-arteritic anterior ischaemic optic neuropathy: a review and update","volume":"16","author":"Kerr","year":"2009","journal-title":"J. Clin. Neurosci. : official journal of the Neurosurgical Society of Australasia"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib188","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2024.01.011","article-title":"Ophthalmic and systemic factors of acute nonarteritic anterior ischemic optic neuropathy in the Quark207 treatment trial","volume":"131","author":"Kupersmith","year":"2024","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib189","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA ophthalmology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"International journal of retina and vitreous"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib191","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2025.118163_bib192","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2025.118163_bib193","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.5149","article-title":"Central retinal artery occlusion with Cilioretinal artery sparing after semaglutide injection","author":"Shabto","year":"2025","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118163_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108472","article-title":"Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial","volume":"37","author":"Gullaksen","year":"2023","journal-title":"J. Diabetes Complicat."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib195","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib197","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib198","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2025.118163_bib199","series-title":"Weight Management","year":"2014"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41443-024-00895-6","article-title":"Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study","volume":"37","author":"Able","year":"2025","journal-title":"Int. J. Impot. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118163_bib201","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41443-024-00960-0","article-title":"Comment on: prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study","volume":"37","author":"Unal","year":"2025","journal-title":"Int. J. Impot. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073073","article-title":"Erectile dysfunction and oxidative stress: a Narrative review","volume":"26","author":"Zhu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118163_bib203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EC-18-0514","article-title":"Effects of liraglutide on obesity-associated functional hypogonadism in men","volume":"8","author":"Jensterle","year":"2019","journal-title":"Endocrine connections"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118163_bib204","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/03007995.2024.2386047","article-title":"The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide","volume":"40","author":"Pinheiro","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2025.118163_bib205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","article-title":"Semaglutide-associated bullous pemphigoid","volume":"15","author":"Burruss","year":"2021","journal-title":"JAAD Case Rep."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118163_bib207","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwac021","article-title":"Glucagon-like peptide 1 receptor agonists and risk of anaphylactic reaction among patients with type 2 diabetes: a multisite population-based cohort study","volume":"191","author":"Pradhan","year":"2022","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118163_bib208","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12020-024-04033-6","article-title":"The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function","volume":"87","author":"Kantreva","year":"2025","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118163_bib209","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/02770903.2024.2372600","article-title":"Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database","volume":"61","author":"Cazzola","year":"2024","journal-title":"J. Asthma : official journal of the Association for the Care of Asthma"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118163_bib210","doi-asserted-by":"crossref","DOI":"10.1177\/03000605251349393","article-title":"Kokalj Palandacic A: association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: a case report","volume":"53","author":"Stojkovska","year":"2025","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118163_bib212","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib213","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118163_bib214","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","article-title":"Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a vigibase study","volume":"51","author":"Nishida","year":"2025","journal-title":"Clinical nutrition (Edinburgh, Scotland)"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118163_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejmech.2025.118163_bib217","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-025-02694-5","article-title":"Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis","author":"Balata","year":"2025","journal-title":"Clin. Res. Cardiol. : official journal of the German Cardiac Society"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118163_bib218","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10571-025-01534-4","article-title":"Beyond diabetes: Semaglutide's role in modulating mood disorders through Neuroinflammation pathways","volume":"45","author":"Pi\u0105tkowska-Chmiel","year":"2025","journal-title":"Cell. Mol. Neurobiol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:53:01Z","timestamp":1773114781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":212,"alternative-id":["S0223523425009286"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118163","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118163"}}